Point Capital, Inc. (39) | License Agreements (4)

Recent Contracts

First Amendment to Commercial Evaluation and License Agreement, dated July 6, 2021, by and between the Company and UMB (Filed With SEC on July 12, 2021)
Amendment No. 1 to Patent License Agreement, dated April 12, 2021, by and among the Company, Silo Pharma, Inc. and AIkido Pharma Inc (Filed With SEC on April 16, 2021)
Master License Agreement, dated February 12, 2021, by and between the Company and the University of Maryland, Baltimore (Filed With SEC on February 16, 2021)
Patent License Agreement by and among the Company and Silo Pharma, Inc., a Florida corporation and their affiliates and subsidiaries and AIkido Pharma Inc (Filed With SEC on January 11, 2021)